biOasis Technologies Appoints New CEO

biOasis Technologies (OTCQB:BIOAF, TSXV:BTI) announced the appointment of Dr. Mark Day as president and CEO of the company.
As quoted in the press release:

Dr. Day most recently served as Head, CNS Virtual Discovery at Purdue Pharma. Prior to joining Purdue, Dr. Day served as Executive Director, Head of External Research & Scouting at Alexion Pharmaceuticals, Inc. Dr. Day also serves as Adjunct Associate Professor (Neuroscience) at Yale University.
Dr. Day is widely recognized for his expertise and success in the recognition, evaluation and development of pipeline acquisition and collaboration targets across several therapeutic areas, including neurotherapeutics and rare diseases. In pursuit of business development opportunities, Dr. Day has evaluated over 300 programs, resulting in a uniquely broad knowledge of the pharmaceutical industry and its opportunities. In the process, he has developed business and personal relationships with many of the industry’s leading executives.

Click here to read the full press release.

Source: www.marketwired.com